ArticleCureus2025
Heterogeneous Changes in Mismatch Negativity Peak Latency Following Electroconvulsive Therapy: A Case Series of Three Cases.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mismatch negativity (MMN), a pre-attentive auditory event-related potential, is a sensitive neurophysiological marker of cortical dysfunction. Electroconvulsive therapy (ECT), which is effective for various psychiatric disorders, may transiently affect cognitive and neurophysiological processes.This case series examined MMN peak latency and cognitive outcomes following ECT in three patients with distinct psychiatric diagnoses: atypical psychosis, treatment-resistant schizophrenia, and major depressive disorder (MDD). In patients with atypical psychosis, MMN peak latency was markedly prolonged immediately after two ECT sessions and returned to baseline by 40 days, in parallel with transient cognitive decline and mild delirium. Conversely, the patient with schizophrenia demonstrated no MMN latency changes and stable cognitive scores, suggesting diminished cortical reactivity, possibly due to chronic illness or medication effects. The patient with MDD, assessed after the final two sessions of a 10-session course, exhibited sustained MMN latency prolongation with preserved cognitive function, indicating potential cumulative subclinical neural effects. These findings highlight the diagnostic and temporal heterogeneity of MMN responses to ECT, with MMN alterations not always correlating with cognitive decline. MMN may serve as a sensitive but nonspecific biomarker of neural instability during ECT, offering clinical value for the early detection of cortical vulnerability. Our results suggest that MMN monitoring, especially when interpreted alongside the diagnosis and treatment stages, may complement standard cognitive assessments and inform individualized ECT management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.